Rheumatology
-
To determine feasibility of TNF inhibitor (TNFi) dose reduction for severe AS and PsA patients. ⋯ In a real-world setting, 60% of individuals with severe AS and PsA who achieve low disease activity can successfully reduce the dose of TNFi therapy by a third for a mean of 1 year.